CD44 and breast cancer: Flow cytometric analysis of breast cancer spheroids treated with 40 μM 6-shogaol for 18 hours (Fig 7A) showed that the percentage of cells characterized by CD44+CD24-/low were substantially less in the treated spheroids when compared to the untreated ones (2.3% vs. 27.3%).